Drug therapy for inflammatory bowel disease in pregnancy and the puerperium

Best Practice and Research in Clinical Gastroenterology

Volumn 21, Issue 5, 2007, Pages 835-847

  Moffatt, Dana C ^a   Bernstein, Charles N ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Crohn's disease; inflammatory bowel disease; lactation; pregnancy; puerperium; treatment; ulcerative colitis

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ATROPINE PLUS DIPHENOXYLATE; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CIPROFLOXACIN; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; FISH OIL; FOLIC ACID; IMMODIUM; IMMUNOMODULATING AGENT; INFLIXIMAB; LOPERAMIDE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLSALAZINE; PREDNISOLONE; PREDNISONE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGE; ARTICLE; BONE MARROW TOXICITY; CLEFT LIP PALATE; CLINICAL TRIAL; CONGENITAL MALFORMATION; CROHN DISEASE; DISEASE ACTIVITY; DISEASE CONTROL; DRUG ACTIVITY; DRUG EXCRETION; DRUG SAFETY; ENTERITIS; HUMAN; LIVER TOXICITY; LOW BIRTH WEIGHT; NEPHROTOXICITY; NONHUMAN; ONSET AGE; PREGNANCY; PREMATURE LABOR; PREMATURITY; PUERPERIUM; REPRODUCTION; STILLBIRTH; TERATOGENICITY; ULCERATIVE COLITIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIDIARRHEALS; FEMALE; FISH OILS; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS; PROBIOTICS; SULFASALAZINE;

EID: 34548684991     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2007.05.002     Document Type: Article

References (84)

1. Gasche C., Scholmerich J., Brynsko J., et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 6 (2000) 8-15
2. Lindhagen T., Bohe M., Valentin L., et al. Fertility and outcome of pregnancy in patients operated on for Crohn's disease. Int J Colorectal Dis 1 (1989) 25-27
3. Willoughby C.P., and Truelove S.C. Ulcerative colitis and pregnancy. Gut 21 (1980) 469-474
4. Fedorkow D.M., Persaud D., and Nimrod C.A. Inflammatory bowel disease: a controlled study of late pregnancy outcome. Am J Obstet Gynecol 160 (1989) 998-1001
5. Briggs G.G., Freeman R.K., and Yaffe S.J. Drugs in pregnancy and lactation. 7th ed. (2005), Lippincott, Williams & Wilkins, Philadelphia, PA
6. Christensen L.A., Rasmussen S.N., and Hansen S.H. Disposition of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid in fetal and maternal body fluids during treatment with different 5-aminosalicylic acid preparations. Acta Obstet Gynecol Scand 73 (1994) 399-402
7. Diav-Citrin O., Park Y.H., Veerasuntharam G., et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 114 (1998) 23-28
8. Norgard B., Fonager K., Pedersen L., et al. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut 52 (2003) 243-247
9. Cornish J.A., Tan E.K., Teare J., et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 56 (2007) 830-837
10. Bell C.M., and Hael F.M. Safety of topical 5-aminosalicylic acid in pregnancy. Am J Gasroenterol 92 (1997) 2201-2202
11. Nelis G.F. Diarrhea due to 5-aminosalicylic acid in breast milk. Lancet 1 (1989) 383
12. Khan A.K., and Truelove S.C. Placental and mammary transfer of sulphasalazine. Br Med J ii (1979) 1553
13. Esbjorner E., Jarnerot G., and Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand 76 (1987) 137-142
14. Craxi A., and Pagliarello F. Possible embryotoxicity of sulfasalazine. Arch Intern Med 140 (1980) 1674
15. Hoo J.J., Hadro T.A., and Von Behren P. Possible teratogenicity of sulfasalazine. N Engl J Med 318 (1988) 1128
16. Norgard B., Czeizel A.E., Rockenbauer M., et al. Population-based case control study of the safety of sulfasalazine use during pregnancy. Aliment Pharmacol Ther 15 (2001) 483-486
17. Khosla R, Willoughby CP, Jewell DP. Crohn's disease and pregnancy. Gut 25:52-56.
18. De Benedetti P.G., Rastelli A., Frassineti C., et al. Structure-activity relationships in dihyropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity. J Med Chem 24 (1981) 454-457
19. Esbjorner E., Jarnerot G., and Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand 7 (1987) 137-142
20. Walker B. Induction of cleft palate in rates with anti-inflammatory drugs. Teratology 4 (1971) 39-42
21. Park-Wylie L., Mazzotta P., Pastuszak A., et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62 (2000) 385-392
22. Rodriguez-Pinilla E., and Martinez-Frias M.L. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology 58 (1998) 2-5
23. Czeizel A.E., and Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 56 (1997) 335-340
24. Robert E., Vollset S.E., Botto L., et al. Malformation surveillance and maternal drug exposure: the MADRE project. Int J Risk Safety Med 6 (1994) 75-118
25. Armenti V.T., Moritz M.J., Cardonick E.H., et al. Immunosuppression in pregnancy: choices for infant and maternal health. Drugs 62 (2002) 2361-2375
26. Ost L., Weetreell G., Bjorkhelm I., et al. Prednisolone excretion in human milk. J Pediatr 106 (1985) 1008-1011
27. Norjaaara E., and De Verdier M.G. Normal Pregnancy outcomes in a population-based study including 2,968 pregnancy women exposed to budesonide. J Allergy Clin Immunol 111 (2003) 736-742
28. Goldstein F. Immunosupressant therapy of inflammatory bowel disease. J Clin Gasroenterol 9 (1987) 654-658
29. Polifka J.E., and Friedman J.M. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 65 (2002) 240-261
30. Alstead E.M., Ritchie J.K., Lennard-Jones J.E., et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 99 (1990) 443-446
31. Moskovitz D.N., Bodian C., Chapman M.L., et al. The effect on the fetus of medications used to treat pregnancy inflammatory bowel-disease patients. Am J Gastroenterol 99 (2004) 656-661
32. Francella A., Dyan A., Present D.H., et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort stud. Gastroenterology 124 (2003) 9-17
33. Moretti M.E., Vergee Z., Ito S., et al. Breast-feeding during maternal use of azathioprine. Ann Pharmacother 40 (2006) 2269-2272
34. Lichtiger S., Present D.H., Kornbluth A., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. New Engl J Med 330 26 (1994) 1841-1845
35. Anderson J.B., Turner G.M., and Williamson R.C. Fulminant ulcerative colitis in late pregnancy and the puerperium. J R Soc Med 80 (1987) 492-494
36. Ramsey-Goldman R.S. Immunosuppressive drug use during pregnancy. Rheum Clin North Am 23 (1997) 149-167
37. Bar Oz B., Hackman R., Einerason T., et al. Pregnancy outcomes after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 71 (2001) 1051-1055
38. Nagy S., Bush M.C., Berkowitz R., et al. Pregnancy outcome in liver transplant recipients. Obstet Gynecol 102 (2004) 121-128
39. Haugen G., Frauchald P., Sodal G., et al. Pregnancy outcome in renal allograft recipients in Norway: the importance of immunosuppressive drug regimen and health status before pregnancy. Acta Obstet Gynecol Scand 73 (1994) 541-546
40. Bertschinger P., Himmelmann A., Risti B., et al. Letters: cyclosporine treatment of severe ulcerative colitis during pregnancy. Am J Gastroenterol 90 (1995) 330
41. Ostensen M. Treatment with immunosuppressive and disease modifying drugs during pregnancy and lactation. Am J Reprod Immunol 28 (1992) 148-152
42. Sifontis N.M., Coscia L.A., Constantinescu S., et al. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 82 12 (2006) 1698-1702
43. Baumgart D.C., Pintffl J.P., Sturm A., et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease - a long term follow up. Am J Gastroenterol 101 (2006) 1048-1056
44. Kainz A., Horabacz I., Cowlrick I.S., et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation 70 (2000) 1718-1721
45. Baumgart D.C., Sturm A., Wiedenmann B., et al. Uneventful pregnancy with neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut 54 (2005) 1820-2821
46. Del Camp M., Kosaki K., Bennett F.C., et al. Developmental delay in fetal aminopterin/methotrexte syndrome. Teratology 60 (1999) 10-12
47. Donnenfield A., Pastuszak A., Noah J.S., et al. Methotrexate exposure prior to and during pregnancy. Teratology 332 (1994) 49
48. Goldenberg M., Bider D., Admon D., et al. Methotrexate therapy of tubal pregnancy. Human Reprod 8 (1993) 660-669
49. Kremer J.M. Toward a better understanding of methotrexate. Arthritis Rheum 50 (2004) 1370-1382
50. Johns D.G., Rutherford L.D., Leighton P.C., et al. Secretion of methotrexate into human milk. Am J Obstet Gynecol 112 (1972) 978-980
51. Ehrenpreis E.D., Kane S.V., Cohen L.B., et al. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial. Gastroenterology 117 (1999) 1271-1277
52. Kane S., and Mahadevan U. American Gastroenterological Association Institute Technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 131 (2006) 283-311
53. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359 (2002) 1541-1549
54. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Inflixiab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
55. Rutgeerts P., Van Assche G., and Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease - seven years on. Aliment Pharmacol Ther 23 (2006) 451-463
56. Srinivasan R. Infliximab treatment and pregnancy outcome in active Crohn's disease. Am J Gastroenterol 96 (2001) 2274-2275
57. Lichtenstein G., Cohen R.D., Feagan B.G., et al. Safety of infliximab in Crohn's disease: data from the 5000-patient TREAT registry. Gastroenterology 126 (2004) A54
58. Mahadevan U., Kane S., Sandborn W.J., et al. Intentional infliximab use during pregnancy for induction or maintenance of remission of Crohn's disease. Aliment Pharmacol Ther 21 (2005) 733-738
59. Vasiliauskas E.D., Barry M., Dubinsky M., et al. High serum levels of infliximab detected in the newborn of a mother receiving during pregnancy. Gastroenterology 128 (2005) P33
60. Vasiliauskas E.A., Church J.A., Silverman N., et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastrenterol Heptaol 4 10 (2006) 1255-1258
61. Peltier M., James D., Ford J., et al. Infliximab levels in breast-milk of a nursing Crohn's patient (abstr). Am J Gastroenterol 96 (2001) P258
62. Cottone M., Mocciaro F., and Scimeca D. Adalimumab induction for Crohn's disease. Gastroenterology 130 (2006) 1929
63. Baker D.R. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody. Rev Gastroenterol Disord 4 (2004) 196-210
64. Mishkin D.S., Van Deinse W., Becker J.M., et al. Successful use of adalimumab for Crohn's disease in pregnancy. Inflamm Bowel Dis 12 (2006) 827-828
65. Vesga L., Terdiman J.P., and Mahadevan U. Adalimumab use in pregnancy. Gut 54 (2005) 890
66. Greenberg F. Possible metronidazole teratogenicity and clefting. Am J Med Genet 22 (1985) 825
67. Cantu J.M., and Garcia-Cruz D. Midline facial defect as a teratogenic effect of metronidazole. Birth Defects 18 (1982) 85-88
68. Diav-Citrin O., Shechtman S., Gotteiner T., et al. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology 63 (2001) 186-192
69. Caro-Paton T., Carvajal A., Martin de Diego I., et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 44 (1997) 179-182
70. Linseman D.A., Hampton L.A., and Branstetter D.G. Quinolone-induced arthropathy in the neonatal mouse: morphologic analysis of articular lesions produced by pipemedic acid and cirprofloxacin. Fundam Appl Toxicol 28 (1995) 59-64
71. Berkovitch M., Pastuszak A., Gasrzarian M., et al. Safety of the new quinolones in pregnancy. Obstet Gynecol 84 (1994) 535-538
72. Lobstein R., Addis A., Ho E., et al. Pregnancy outcome following gestational exposure to fluroquinolones: a multicentre prospective controlled study. Antimicrob Agents Chemother 42 (1998) 1336-1339
73. Prantera C., Scribano M.L., Falasco G., et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomized controlled trial with lactobacillus GG. Gut 51 (2002) 405-409
74. Guslandi M., Giollog P., and Testoni P.A. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15 (2003) 697-698
75. Chapman T.M., Plosker G.L., and Figgitt D.P. VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases. Drugs 66 (2006) 1371-1387
76. Rautava S., Kalliomaki M., and Isolauri E. Probiotics during pregnancy and breastfeeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 109 1 (2002) 119-121
77. Rinne M., Kalliomaki M., Arvilommi H., et al. Effect of probiotics and breastfeeding on bifidobacterium and lactobacillus/enterococcus microbiota and humoral immne responses. J Pediatr 147 2 (2005) 186-191
78. Mozaffarian D., and Rimm E.B. Fish intake, contaminants, and human health: evaluating the risks and benefits. J Am Med Assoc 296 15 (2006) 1885-1899
79. Olsen S.F., Sorensen J.D., Secher N.J., et al. Randomised controlled trial of effect of fish-oil supplementation on pregnancy duration. Lancet 339 (1992) 1003-1007
80. Allen K.G., and Harris M.A. The role of n-3 fatty acids in gestation and parturition. Exp Biol Med 226 6 (2001) 498-506
81. Jensen C.L. Effects of n-3 fatty acids during pregnancy and lactation. Am J Nutr 83 Suppl. 6 (2006) 1452S-1457S
82. Einarson A., Mastroiacovo P., Arnon J., et al. Prospective, controlled, multi-centre study of loperamide in pregnancy. Can J Gastroenterol 3 (2000) 185-187
83. Bonapace Jr. E.S., and Fisher R.S. Constipation and diarrhea in pregnancy. Gastroenterol Clin North Am 27 (1998) 197-211
84. Sauk J., and Kane S. The use of medications for inflammatory bowel disease during pregnancy and nursing. Expert Opin Pharmacother 6 11 (2005) 1833-1839